Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
2016/12/06 by Oliver D. Howes, Oliver Howes, Robert A. McCutcheon +64 · 35 citations
Medicine · Arts and Humanities · #Schizophrenia research and treatment #Treatment of Major Depression #Mental Health and Psychiatry
paper · pdf · doi:10.1176/appi.ajp.2016.16050503
Abstract
OBJECTIVE: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines. METHOD: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted. Subsequently, consensus operationalized criteria were developed through 1) a multiphase, mixed methods approach, 2) identification of key criteria via an online survey, and 3) meetings to achieve consensus. RESULTS: Of 2,808 studies identified, 42 met inclusion criteria. Of these, 21 studies (50%) did not provide operationalized criteria. In the remaining studies, criteria varied considerably, particularly regarding symptom severity, prior treatment duration, and antipsychotic dosage thresholds; only two studies (5%) utilized the same criteria. The consensus group identified minimum and optimal criteria, employing the following principles: 1) current symptoms of a minimum duration and severity determined by a standardized rating scale; 2) moderate or worse functional impairment; 3) prior treatment consisting of at least two different antipsychotic trials, each for a minimum duration and dosage; 4) systematic monitoring of adherence and meeting of minimum adherence criteria; 5) ideally at least one prospective treatment trial; and 6) criteria that clearly separate responsive from treatment-resistant patients. CONCLUSIONS: There is considerable variation in current approaches to defining treatment resistance in schizophrenia. The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation.
Cited by
- Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance
- Clozapine facilitates sustained improvement in psychotic symptoms with a subsequent cascade of effects on functioning and quality of life
- Towards a rational ECT treatment approach for severe and treatment resistant schizophrenia using neuroimaging biomarkers: A focused review
- Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
- A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology
- Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study
- <i>Australian and New Zealand Journal of Psychiatry</i> Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophrenia
- Clozapine Efficacy and Adverse Drug Reactions Among a Nationwide Study of 1021 Australians Prescribed Clozapine: The ClozaGene Study
- Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
- Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. [europepmc]
- Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis. [europepmc]
- Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. [europepmc]
- Determinants of treatment response in first-episode psychosis: an 18 F-DOPA PET study. [europepmc]
- Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. [europepmc]
- Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. [europepmc]
- Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. [europepmc]
- A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis. [europepmc]
- Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. [europepmc]
- Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review. [europepmc]
- Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. [europepmc]
- Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial. [europepmc]
- Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. [europepmc]
- The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. [europepmc]
- 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). [europepmc]
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. [europepmc]
- Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. [europepmc]
- A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology. [europepmc]
- The clinical characterization of the patient with primary psychosis aimed at personalization of management. [europepmc]
- The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. [europepmc]
- Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. [europepmc]
- Treatment resistance in psychiatry: state of the art and new directions. [europepmc]
- Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review. [europepmc]
- Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. [europepmc]
- A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. [europepmc]
Related